Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia
PDF) Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports
![PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7550a5cdc69f479a7aec573d63770ee1c9f77045/5-Figure1-1.png "PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar")
PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi - The Lancet Haematology
Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
Low-dose and high-dose chemotherapy regimens | Download Table
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
Clinical Trial Results with Novel Agents and Regimens for the Treatment of Newly Diagnosed or Relapsed/Refractory AML/MDS, Including in the Elderly | Research To Practice
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483) | Leukemia
Hematologic Malignancies - ppt download
![PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7550a5cdc69f479a7aec573d63770ee1c9f77045/6-Figure2-1.png "PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar")
PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients - ScienceDirect
Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) - ScienceDirect
TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE | Mediterranean Journal of Hematology and Infectious Diseases
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial - The Lancet Haematology
Uproleselan Added to Cladribine Plus Low-Dose Cytarabine (LDAC) In Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)
Prevention and Treatment of Cytarabine-Induced Keratoconjunctivitis
Low-dose cytarabine reduces mortality in TMD patients – Leukemia Research
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia
Comparison network. Notes: In the above comparison network, LDAC alone... | Download Scientific Diagram
Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
1182-Low dose cytarabine | eviQ
